Vir Biotechnology announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6. Dr. Towne will be responsible for leading the Company’s research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir‘s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company’s Executive Management Team.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VIR:
- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
- Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
- Vir awarded BARDA funding for development of antibody platform technology
- Vir Biotechnology participates in a conference call with JPMorgan
